Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Pulmonary Disease, Chronic Obstructive 1Lung Neoplasms 1Disease 1Diabetes Mellitus, Type 2 1

Interventions

Carboplatin 351pembrolizumab 327Pemetrexed 249Cisplatin 221Paclitaxel 149Nivolumab 139durvalumab 134Docetaxel 112osimertinib 111atezolizumab 107Specimen Handling 91Radiotherapy 89Drug Therapy 87Magnetic Resonance Spectroscopy 78Etoposide 78Radiosurgery 74Gemcitabine 72Ipilimumab 55130-nm albumin-bound paclitaxel 54Bevacizumab 53cemiplimab 47tislelizumab 46Blood Specimen Collection 43Cetuximab 35Taxes 34Injections 33Biopsy 33Standard of Care 32Platinum 32Immunoglobulin G 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dipeptidyl-Peptidase IV Inhibitors × Thoracic × 1 year × Clear all
NCT07332156 2026-01-14

Lung Cancer Risk in Type 2 Diabetes With COPD: SGLT2 Inhibitors vs. Sulfonylureas

Samsung Medical Center

Completed
21,692 enrolled
Thoracic

Diabetes Mellitus, Type 2, Disease, Lung Neoplasms, Pulmonary Disease, Chronic Obstructive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡